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CII = collagen type II; CIX = collagen type IX; CXI = collagen type XI; COMP = cartilage oligomeric matrix protein; HLA = human leukocyte antigen;
RA = rheumatoid arthritis; RP = relapsing polychondritis.
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Introduction
Relapsing polychondritis (RP) is a rare disorder which pri-
marily affects cartilage in the upper respiratory tract, the
ears and the nose. Joints are affected as well, but as a
non-erosive arthritis. Like rheumatoid arthritis (RA), RP has
been associated with the HLA-DR4 molecule in a few
studies. In addition, patients with RP and RA present
symptoms within the same cartilage structures, but with
large variations in severity. Animal models that mimic the
symptoms of the human disorder could be used as a tool
to investigate the pathogenic mechanisms of RP. Several
animal models for RP have been reported and the majority
of them describe chondritis of the joints and ears [1,2].
We recently reported that immunization with matrilin-1, a
protein restricted to upper respiratory tract cartilage,
induced chondritis in the respiratory tract and nose but
not arthritis [3]. The matrilin-1-induced model was the first
report of an animal model with a chronic inflammatory
disease specifically directed to the upper respiratory tract
and which did not affect other cartilage-containing parts of
the body, such as the joints.
The aim of this review is to describe potential target anti-
gens that are involved in the pathogenesis of RP and
related autoimmune diseases in which cartilage is
affected by inflammation. We will discuss how these anti-
gens may contribute to the induction of different symp-
toms in the animal models and in the patients. We will
give a summary of the characteristic symptoms that
appear in the patients and that are of importance for the
understanding of the different phenotypes in the respec-
tive model. Lastly we will address the heterogeneity and
specificity of the cartilage inflammation detected in the
animal models and in the patients.
Symptoms and diagnosis of patients with
relapsing polychondritis
RP is a systemic autoimmune disease that appears in
cycles. Several cartilage structures are affected by inflam-
mation and the diagnosis is mainly based on the symp-
toms that result from this chondritis. Three out of the
following six criteria, including a histological confirmation,
are needed for a positive diagnosis [4]:
Relapsing polychondritis is an autoimmune disease in which an inappropriate immune response
destroys cartilage. Cartilage of the ears, larynx and nose rather than spine and joint cartilage is affected
by a chronic relapsing and erosive inflammation. Several animal models for relapsing polychondritis
have been published in which immunization with various cartilage proteins induces a variety of
chondritis symptoms that mimic those seen in patients. In this review we describe the collagens,
matrilin-1 and cartilage oligomeric matrix protein as potential autoantigens able to trigger the tissue-
specific immune response seen both in patients and in animal models for relapsing polychondritis and
related autoimmune diseases.
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1. Bilateral auricular chondritis
2. Non-erosive sero-negative inflammatory polyarthritis
3. Nasal chondritis
4. Ocular inflammation
5. Respiratory tract chondritis
6. Audiovestibular damage
The most characteristic symptom is an inflammation of the
external ear, subsequently leading to ‘cauliflower’ ears
with sometimes severe tissue deformation [4,5]. Large
and peripheral small joints are affected by inflammation in
an asymmetric, episodic and migratory manner. Contrary
to RA, no rheumatic factor is detected in sera from RP
patients and the arthritis is considered to be non-erosive,
although erosions may appear in late stages of the
disease. Inflammation and erosion of cartilage in the nasal
septum is common and occasionally results in the appear-
ance of a ‘saddle-nose’ deformity (Fig. 1). In half of the RP
patients the cartilage of the tracheolaryngeal tract is
affected. This is a potentially fatal symptom caused by a
collapse of tracheal rings and bronchi and/or by inflamma-
tory obstruction of the airways. These patients experience
dyspnea, cough, stridor and (in some cases) symptoms
from severe cyanosis. One fifth of the patients develop
complications from nephritis, which is commonly associ-
ated with extrarenal vasculitis. Noncartilaginous structures
such as the skin and cardiovascular system are commonly
affected by inflammation as well, the latter accounting for
a fatal outcome in some patients. All symptoms appear in
episodes and are most often found as manifestations from
chondritis at specific sites.
As for many other autoimmune diseases, there have been
reports of a correlation between RP diagnosis and the
MHC class II region [6,7]. The serotype HLA-DR4 was
found with a significantly higher frequency (50–60%) in
RP patients than in healthy controls (25%) and HLA-DR-
positive cells were detected in the auricular cartilage from
an RP patient with active disease [8]. No correlation to
any subtype allele has so far been reported. Furthermore,
30% of the RP patients tested also have other auto-
immune diseases, RA being the most common [4]. Taking
into account that the prevalence of RP is low, this still
highlights a role for the MHC molecule in RP and also indi-
cates that shared pathogenic pathways might be used in
RP and RA. As large variations in the severity and targets
of the inflammatory attack appear in patients with RP and
RA, differently expressed antigens must trigger the
immune system in these patients.
Potential target autoantigens in relapsing
polychondritis
Several cartilage proteins are considered to be potential
target antigens in RP. Some of these are also proposed to
trigger an immune response in RA. Animal models for RP
have been described as those immunized with either colla-
gen type II (CII) or matrilin-1 and as models that appear
spontaneously [1–3]. These models differ in clinical fea-
tures as well as in immunological properties, and the major
phenotypic findings are described in this section.
The collagens
Three types of collagen are discussed as playing a role in
RP pathogenesis: CII, collagen type IX (CIX) and collagen
type XI (CXI). These types are almost exclusively detected
in cartilage, where CII, a triple-helical peptide, represents
85% of the total collagen content whereas the minor colla-
gens, CIX and CXI, represent 5–10% [9]. They are
assembled into cartilage fibrils that are mainly composed
of CII fibers with CXI integrated internally and CIX situated
on the external part of the fibrils.
An increased immune response to CII is believed to play a
role in RA; several investigators have also found antibod-
ies to CII in patients with RP [10–13]. Anti-CII antibodies
in RP patients are directed against both native and dena-
tured CII, but, as in RA, it has not been possible to deter-
mine whether this reflects cross-reactivity of antibodies to
the collagen triple helix or if there are also important anti-
bodies specific to denatured CII. The epitope specificities
of the anti-CII antibodies differ between RP and RA, which
could contribute to the differences in arthritis phenotypes
Figure 1
Patient with RP presenting nasal chondritis and saddle-nose deformity.
Reproduced courtesy of Dr S Foster, Immunology and Uveitis Service,
Massachusetts Eye & Ear Infirmary, Boston, MA, USA.298
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in the two diseases [14]. CIX and CXI are also targets for
an antibody production in RP patients [15,16]. Surpris-
ingly, a more prominent response was seen for CIX and
CXI in a patient presenting a fatal tracheomalacia, indicat-
ing CIX and CXI rather than CII as being involved in chon-
dritis of the respiratory tract [17].
The humoral response has been the main target for inves-
tigation in RP patients, but recently T-cell clones from an
RP patient were reported to respond to the CII peptide
residues 261–273 bound to the DR4 (*0401) molecule
[18]. In a separate report, T-cell responses to CIX and CXI
were found in a patient with severe tracheomalacia [17].
Animals immunized with CII develop articular and auricular
chondritis [1,19]. The most dominating symptom is inflam-
mation in the peripheral joints characterized by redness,
swelling and pain, which mimic the symptoms of arthritis in
RP patients. In the majority of the rodent strains, however,
this inflammation is erosive and symmetric. This is in con-
trast to symptoms in RP patients, who instead develop a
non-erosive and asymmetric arthritis. Auricular chondritis
in mice as well as in rats has been reported. It presented
as erythema, thickening and induration of the affected car-
tilage [1,20,21]. It appeared after the onset of arthritis,
which indicates the mechanism of auricular chondritis to
be a secondary phenomenon to joint inflammation. CII
immunization can also induce inflammation in the nasal
and tracheolaryngeal cartilage, but only at a microscopic
level [22].
Matrilin-1
Considering that cartilage tissue outside the diarthrodial
joints is affected in RP patients, an immune response is
likely to be induced against a cartilage protein expressed
in the extra-articular cartilage. Matrilin-1 is a minor non-
collagenous protein that, contrary to previously identified
cartilage proteins, is mainly detected in the tracheal car-
tilage and is not found in the articular cartilage. To some
extent it is found in nasal and auricular cartilage [23,24].
Consequently, matrilin-1 is a major candidate autoanti-
gen for the induction of inflammation in cartilage outside
the joints.
Matrilin-1 is a 148 kDa extracellular cartilage-specific gly-
coprotein with high stability that, upon reduction of disul-
fide bonds, dissociates into three subunits [23,25,26].
Antibodies to matrilin-1 have been detected in sera from
13 out of 97 RP patients [13]. In 9 out of these 13, symp-
toms in the respiratory tract were evident and in some
cases fatal respiratory distress appeared. In addition, a
humoral as well as a cellular response to matrilin-1 was
reported in a single patient with respiratory symptoms
[27]. Furthermore, the level of circulating matrilin-1 corre-
lated with pronounced respiratory symptoms in one RP
patient, which indicated destruction of the tracheolaryn-
geal cartilage during active disease [28].
In animal models matrilin-1 plays a unique role in the
induction of chondritis in the respiratory tract. Recently we
presented a new animal model for RP that mimics symp-
toms originating in the nose and respiratory tract. Both
mice and rats immunized with matrilin-1 developed inspira-
tory distress that appeared in cycles [3]. Symptoms in the
rodents mimicked those seen in human RP, so the model
was named matrilin-1-induced relapsing polychondritis.
Rats of some strains also presented spontaneous nose
bleedings and macroscopic hematuria, although these
symptoms were not observed in mice. Joints were not
affected in either species. In tissue sections, aggressive
inflammation and erosions of the affected cartilage con-
firmed the clinical signs (Fig. 2). As measured by antibody
response, all strains responded strongly to matrilin-1 and
in some cases also to CII and CIX, but no correlation with
clinical symptoms was found. Both MHC and non-MHC
genes were confirmed to be involved in pathogenesis. We
concluded that the rat model was dependent on CD4+ αβ
T cells. In addition, monoclonal antibodies to matrilin-1
induced an erosive inflammation of the laryngeal cartilage
when injected into adult mice, which indicates that anti-
bodies specific to matrilin-1 are pathogenic in the murine
model (Hansson et al., unpublished data).
Cartilage oligomeric matrix protein
Cartilage oligomeric matrix protein (COMP) is an addi-
tional cartilage protein discussed in relation to RP patho-
genesis. COMP is expressed in auricular, tracheal and
nasal cartilage and consequently has the potential to
trigger an immune response directed against all these car-
tilaginous structures [29]. Only joints were affected in
immunized rats, however [30]. Circulating COMP as well
as antibodies to COMP were detected in sera from RP
patients [13,28].
Additional arthritis models and spontaneous models
Several other models for arthritis have been reported but
these will not be discussed here. We believe that they
should be considered as alternative models for investigat-
ing the mechanisms of joint inflammation. Aggrecan [31]
and the aggrecan-associated link protein [32] are two
examples of such cartilage proteins that trigger arthritis in
mice but that have not yet been investigated in RP
patients. Adjuvants and oils can induce arthritis in many rat
strains [33–36] and auricular chondritis in Wistar rats
[21]. Finally, in FH and Wistar rats, chondritis may appear
spontaneously in the outer ears [2,37,38]. Cartilage speci-
ficity in these spontaneous models is not yet known.
Conclusion
It is important to understand the development of RP, not
only for improving predictive diagnosis and therapy, but299
also because its resemblance in terms of genotype and
phenotype to RA might help us to highlight some path-
ways of common importance in the two diseases. Animal
models of both RP and RA have been reproduced and are
now powerful tools to elucidate the basic mechanisms of
autoimmune chondritis.
A major genetic influence in several autoimmune diseases
has been reported. An association between the HLA-DR4
haplotypes and RA has been acknowledged for many
years. Interestingly, a similar association has been
reported in RP. The low number of RP patients as well as
the paucity of studies on these patients complicates the
genetic analysis. Studies of animal models for RP and RA
show several differences regarding the correlation
between genotypes and susceptibility to disease. Surpris-
ingly, the DA rat, known to be highly susceptible in most
arthritis models, was resistant to immunization with
matrilin-1, whereas the LEW.1A rat, carrying the same
MHC alleles as the DA rat, was a high responder [3]. In
the murine models, preliminary data indicate that similar
strains, carrying the Q haplotype, develop disease in the
matrilin-1-induced relapsing polychondritis and in the col-
lagen-induced arthritis models (Hansson et al., unpub-
lished data) [39]. It has also been reported that
HLA-DQ6αβ/8αβ doubly transgenic mice developed
severe polychondritis (auricular as well as articular) after
CII immunization. Severe arthritis was observed in the
singly transgenic HLA-DQ8αβ mice, whereas none of the
singly transgenic variants developed auricular chondritis
[20]. Taken together these data show that several genes,
non-MHC as well as MHC, are involved in the pathogene-
sis of RP. Some of these genes are similar to the ones
associated with RA, which indicates that similar patho-
genic mechanisms may be valid for autoantigen presenta-
tion in RP and RA. We can also conclude that different
genes in the MHC class II complex are involved in the
induction of chondritis at different locations, suggesting that
several autoantigens contribute to the clinical heterogeneity.
For unknown reasons, cartilage in synovial joints is more
easily accessible to an immune attack than extra-articular
cartilage. Immunization with most of the cartilage proteins
tested as well as several adjuvants induces arthritis but no
extra-articular inflammation. This indicates that the joint
possesses structural and/or functional properties that are
not present in extra-articular cartilage. It has been pro-
posed that the joint cartilage surface presents an environ-
ment lacking inhibitors of complement-mediated
inflammatory pathways [40] or is more prone to attract
antibody binding [41]. The recognition of cartilage as an
immunoprivileged site, and specific factors such as the
possibility that the synovial lining harbors unique immuno-
competent cells, also need consideration.
What determines the initial triggering of a cartilage-spe-
cific immune response, its outcome and subsequent
symptoms is poorly understood. Most likely the distribution
and concentration of a particular cartilage protein play a
role in determining the symptoms and their localization.
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Figure 2
Sections of cartilaginous tissues from a female LEW.1F rat immunized with matrilin-1 [3]. An erosive inflammation is detected in the nasal septum
(a) and in the laryngeal part of the respiratory tract (b) with an influx consisting mainly of neutrophils but also of lymphocytes, macrophages and
eosinophils. Hematoxylin and erythrosine staining. Reproduced with the permission of the American Society for Clinical Investigation Inc.300
This is demonstrated in the matrilin-1-induced relapsing
polychondritis model, in which matrilin-1 plays a unique
role in the induction of tracheolaryngeal chondritis. CII is
regarded as a potential autoantigen in both RP and RA,
but specificity of the CII autoantibodies that are produced
differs between the two diseases. Interestingly, the CII
peptide 261–273, known as a DR4- and DR1-immun-
odominant T-cell epitope in RA, was recently identified as
the CII epitope for T-cell clones from an RP patient het-
erozygous for the HLA-DR allele (DRB1*0101/
DRB1*0401) [18,42]. This further supports the theory that
a number of different epitopes are significant in the devel-
opment of cartilage autoimmunity.
Variations in epitope selection might explain the diversity
in clinical outcome observed not only in patients with RP
and RA but also in patients with the same diagnosis. The
role of the CII peptide 261–273 in RP needs to be con-
firmed in separate reports and additional studies are
needed in order to identify and define cartilage-specific
epitopes in the initial phase of chondritis as well as in the
recurrent relapses.
In conclusion, RP is a disease that affects a unique combi-
nation of cartilaginous structures. Several cartilage pro-
teins, some of which are also important for the induction of
RA, play a role in RP pathogenesis. Animal models provide
good tools in the search for potential autoantigens and
candidate genes in RP, RA and related autoimmune dis-
eases. Further knowledge of the cartilage-specific immune
response will be useful in developing strategies for pro-
tecting selected cartilage tissue from an autoimmune/
inflammatory attack, regardless of disease diagnosis.
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